CD274 and neoplasm: In addition to PD-L1 and driver oncogenes, circulating tumor DNA (ctDNA) has been proposed as another candidate biomarker for DC, which could predict recurrence (minimal/molecular residual disease) following curative-intent treatment and the response of immune checkpoint inhibitor consolidation [37,38].